Zhejiang Medicine Co., Ltd. (SHSE: 600216)
Health Care · Pharmaceuticals · CN
CN¥13.23
-0.75% today · -19.1% 1Y
Zhejiang Medicine Co., Ltd. (SHSE: 600216) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.87B and employs 5,417 people.
Over the last twelve months the share price has lost 19.1%, trading between 10.94 and 18.58.
Tweenvest scores Zhejiang Medicine Co., Ltd. across four factors: quality 76/100, value 67/100, growth 21/100, dividend 43/100. Its strongest factor is quality.
600216 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.87B
- Revenue (TTM)
- $1.28B
- P/E
- 16.94
- EPS
- 0.78
- Dividend yield
- 2.12%
- Beta (5Y)
- 0.32
- 52-week high
- CN¥18.58
- 52-week low
- CN¥10.94
- Avg volume (3M)
- —
- Shares outstanding
- 947.91M
- Employees
- 5,417
- Next earnings
- —
About Zhejiang Medicine Co., Ltd.
Zhejiang Medicine Co., Ltd. is a Chinese enterprise specializing in the manufacturing and distribution of both nutritional supplements and pharmaceutical goods. Its life nutrition portfolio encompasses a wide array of offerings, such as synthetic and natural vitamin E, vitamin A, vitamin H, vitamin D3, coenzyme Q10, carotene, cantharidin, lutein, and lycopene, alongside various other vitamin compounds. Beyond nutrition, the company is a significant supplier in the pharmaceutical sector. This includes the production of active pharmaceutical ingredients and raw materials like specialized antibiotics for drug-resistant strains, anti-malarial compounds, and quinolone derivatives. Furthermore, it develops and markets finished pharmaceutical products, notably sugar-based medications and hormonal preparations. Established in 1997, Zhejiang Medicine Co., Ltd. maintains its headquarters in Shaoxing, China.
- ISIN
- CNE0000010J2
- Founded
- 1997
- Listed since
- Oct 21, 1999
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.